EU: Malaria drugs used for virus could cause side effects

Image
AP London
Last Updated : Apr 23 2020 | 8:34 PM IST

The European Union's medicines regulator on Thursday warned countries that malaria drugs being used experimentally to treat the new coronavirus have potentially serious side effects, including seizures and heart problems.

The European Medicines Agency said in a statement that chloroquine and hydroxychloroquine two medicines embraced by US President Donald Trump and others as a potential COVID-19 treatment are known to cause heart rhythm problems, especially if combined with other drugs.

There is currently no licensed treatment for COVID-19 and dozens of trials are under way globally.

Chloroquine and hydroxychloroquine have long been used to treat malaria and anti-inflammatory diseases like rheumatoid arthritis.

In addition to the heart problems, the two drugs can also cause side effects including liver and kidney damage, seizures, and result in low blood sugar.

"Clinical data are still very limited and inconclusive, and the beneficial effects of these medicines in COVID-19 have not been demonstrated," the EMA said.

It noted that several clinical trials testing the drugs' effectiveness against the coronavirus are using higher than recommended doses, which it said could increase the risk of side effects including abnormal electric activity that could disrupt the heart rhythm.

Earlier this month, part of a study in Brazil was suspended after doctors found one quarter of patients taking chloroquine developed irregular heart rhythms after taking a higher dose.

The EMA reminded doctors and patients to report any suspected side effects from hydroxychloroquine and chloroquine to national authorities.

"These must not be used without a prescription and without supervision from a doctor," the agency said.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 23 2020 | 8:34 PM IST

Next Story